HUMAN ALBUMIN GRIFOLS Drug Profile

Summary for Tradename: HUMAN ALBUMIN GRIFOLS

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for HUMAN ALBUMIN GRIFOLS

Recent Clinical Trials for HUMAN ALBUMIN GRIFOLS

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Hospital Clinic of Barcelona	Phase 2

See all HUMAN ALBUMIN GRIFOLS clinical trials

Pharmacology for HUMAN ALBUMIN GRIFOLS

Ingredient-type	Serum Albumin
Mechanism of Action	Osmotic Activity
Physiological Effect	Increased Intravascular Volume Increased Oncotic Pressure
Established Pharmacologic Class	Human Serum Albumin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HUMAN ALBUMIN GRIFOLS Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HUMAN ALBUMIN GRIFOLS Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for HUMAN ALBUMIN GRIFOLS Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352		2032-10-10	Patent claims search
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352		2036-12-20	Patent claims search
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352		2035-10-02	Patent claims search
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352		2033-03-04	Patent claims search
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352		2036-02-23	Patent claims search
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352		2037-05-19	Patent claims search

Market Dynamics and Financial Trajectory for Grifols' Human Albumin

Last updated: April 16, 2026

What is the current market size and growth outlook for human albumin?

The global human albumin market was valued at approximately USD 3.7 billion in 2022. The compound annual growth rate (CAGR) is projected around 6.2% from 2023 to 2030. Factors driving growth include increasing demand for plasma-derived therapies, aging populations, and rising prevalence of conditions such as burns, trauma, and liver cirrhosis. Regional variations show North America holding roughly 40% of market share, followed by Europe at 25%, with Asia-Pacific experiencing the fastest growth due to expanding healthcare infrastructure and rising patient populations.

How does Grifols’ human albumin product position itself in the market?

Grifols’ human albumin product, derived from plasma, is among the top-selling treatments globally. It benefits from decades of brand recognition and a broad distribution network. The company's integrated plasma collection systems ensure a consistent supply chain, which is critical given the product's high dependence on plasma donations. Grifols asserts to hold a market share estimated at 15-20%. Its focus on quality assurance, diverse portfolio, and expansion into emerging markets reinforce its competitive positioning.

What are the key drivers affecting the supply and demand of human albumin?

Supply chain factors:

• Plasma collection infrastructure—Grifols operates over 60 plasma donation centers globally, increasing its capacity to meet rising demand.

• Regulatory approvals—product licenses in multiple jurisdictions (e.g., FDA, EMA).

• Manufacturing capacity—investment in new fractionation facilities, with a notable USD 500 million plant in Spain expected to boost annual production by 20%.

Demand factors:

• Clinical applications—used in hospitals for volume expansion in trauma, burns, hypoproteinemia, and surgical procedures.

• Demographic trends—aging populations, increasing chronic liver diseases, and prevalence of critical care conditions.

• Replacement products—limited, as albumin is primarily plasma-derived, making substitutes less effective for many indications.

Market constraints include supply shortages and high production costs due to plasma dependence.

How have recent financial performances and R&D investments focused on human albumin?

Grifols' overall revenues for 2022 totaled USD 6.0 billion. Human albumin sales accounted for approximately USD 1.2 billion, representing roughly 20% of total revenue. The segment experienced a 4% year-over-year growth, driven by expanded market access and new indications.

The company invested USD 300 million in 2022 into R&D, with around USD 60 million allocated directly to plasma-derived therapies, including albumin. R&D efforts focus on:

• Developing improved formulations with extended shelf life.

• Exploring recombinant alternatives to reduce dependence on plasma.

• Investigating novel indications, such as neurodegenerative diseases.

Operational improvements and capacity expansions underpin sales growth in this segment.

How do regulatory and geopolitical factors influence the market trajectory?

Regulatory approval processes can delay product launches or restrict access in key markets. Recent changes include:

• Stricter plasma donation regulations in China, limiting plasma exports, impacting supply.

• Approval of biosimilar albumin products in select jurisdictions, increasing competition.

• US Food and Drug Administration (FDA) approval for plasma collection methods that can enhance yield efficiency.

Geopolitical tensions or export restrictions may constrain plasma import/export flows, affecting global supply chains. Additionally, demand for plasma-derived therapies remains sensitive to healthcare policy changes and reimbursement frameworks.

What are future growth opportunities and challenges?

Growth opportunities:

• Expansion into emerging markets with rising healthcare infrastructure.

• Innovation in recombinant albumin to lower costs and improve supply reliability.

• Potential for new therapeutic indications, driven by ongoing clinical trials.

Challenges:

• Dependence on plasma supply, susceptible to donor availability and regulatory shifts.

• Competition from biosimilars and recombinant products.

• High manufacturing costs necessitate scale to maintain margins.

• Regulatory hurdles in different jurisdictions may delay product commercialization.

Financial outlook and strategic considerations

Projected revenues for human albumin could reach USD 1.5 billion by 2030, assuming sustained CAGR and market expansion. Profit margins are expected to improve with capacity expansions and technological advancements reducing production costs.

Strategic investment in plasma collection infrastructure and R&D for recombinant variants will be key to maintaining competitive advantage. Price pressures due to biosimilar entry and reimbursement policies need monitoring.

Key takeaways

• The human albumin market is expanding steadily, driven by demographic changes and clinical demand.

• Grifols commands a significant market share but faces supply constraints and rising competition.

• Revenue from human albumin contributes substantially to Grifols' overall financial performance.

• Technological innovation and expansion into emerging markets remain catalysts for future growth.

• Regulatory and geopolitical developments pose ongoing risks to supply and market access.

FAQs

1. What is the primary source of human albumin?
Plasma donations from healthy donors.

2. Can recombinant albumin replace plasma-derived versions?
Research is ongoing; recombinant albumin has potential but is not yet commercially dominant.

3. How does plasma donation regulation affect production capacity?
Tighter regulations can limit plasma collection, reducing supply and increasing production costs.

4. What are the main indications for human albumin?
Treatment of hypoproteinemia, volume expansion in trauma and surgery, and burns.

5. What competitive efforts are underway in this market?
Development of biosimilars, recombinant variants, and expansion into emerging regions.

---

References

1. MarketWatch. (2023). Human Albumin Market Size, Share & Trends.
2. Grifols. (2022). Annual Report 2022.
3. The Business Research Company. (2023). Plasma Protein Therapeutics Market Size.
4. FDA. (2022). Regulatory Approvals for Plasma-Derived Products.
5. European Medicines Agency. (2022). Approval for Albumin Use in EU.